Exocrine Pancreatic Insufficiency (EPI) Market

Oral is projected to lead route of administration at 91.0% share in 2026, followed by pancreatic enzyme replacement therapy as expected to garner 74.0% share of treatment in 2026. Clinical diagnosis and meal-linked dosing support recurring therapy use, with underdiagnosis and supply interruptions forming principal barriers.